💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Ex-drug CEO Shkreli plans to replace lawyers

Published 01/19/2016, 12:21 PM
Updated 01/19/2016, 12:30 PM
© Reuters. Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn in New York
TWTR
-

By David Ingram

NEW YORK (Reuters) - Former drug executive Martin Shkreli plans to hire new legal counsel to represent him against U.S. charges that he defrauded investors at his former hedge fund and a pharmaceutical company he headed, Shkreli's current lawyers said.

Defense lawyers from the law firm Arnold & Porter said in court papers filed on Monday in Brooklyn federal court that Shkreli indicated he wished to replace them and was in the process of retaining new lawyers.

The reason for the lawyer switch was not known. The lawyers did not cite a reason and could not immediately be reached on Tuesday. Shkreli also could not immediately be reached.

Shkreli, who sparked a public uproar last year after he drastically raised the price of a life-saving prescription drug, has maintained a combative stance since his arrest last month on fraud charges.

He frequently posts to Twitter (N:TWTR), and in media interviews, including one on Sunday with television station WNYW, has said federal prosecutors unfairly targeted him with a "fictitious" case.

A spokeswoman for prosecutors declined to comment.

Shkreli pleaded not guilty last month to charges that he ran his companies like a Ponzi scheme, using each subsequent company to pay off defrauded investors from a prior company. After his arrest, he stepped down as chief executive of Turing Pharmaceuticals and was fired as chief executive of KaloBios Pharmaceuticals. KaloBios also filed for bankruptcy.

A hearing in Shkreli's case is scheduled for Wednesday, but the change in lawyers should mean a delay, the Arnold & Porter lawyers said.

"We respectfully request a two-week continuance of the scheduled conference so that Mr. Shkreli can finalize his engagement of new counsel and we can properly transition the matter to the new attorneys," wrote the lawyers, Marcus Asner and Baruch Weiss.

© Reuters. Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn in New York

The case is U.S. v. Shkreli, U.S. District Court for the Eastern District of New York, No. 1:15-cr-637.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.